Samsung Bioepis Partners with ATLATL to Boost Asia-Pacific Biotech Innovation
Event summary
- Samsung Bioepis and ATLATL signed an MoU on April 28, 2026 to accelerate early-stage biotech innovation in the Asia-Pacific region.
- The partnership leverages ATLATL’s extensive network as one of the largest biotech incubation centers in APAC.
- Samsung Bioepis plans to launch the Innovation Prize program with ATLATL to support selected early-stage biotech companies.
The big picture
This collaboration underscores the growing importance of external innovation in drug development, particularly in emerging markets like Asia-Pacific. By tapping into ATLATL’s robust R&D network, Samsung Bioepis aims to strengthen its pipeline and foster a broader innovation ecosystem. The partnership reflects a strategic shift towards open innovation models to drive efficiency and impact in biotech.
What we're watching
- Program Success
- How the Innovation Prize program will impact the growth and development of early-stage biotech companies in APAC.
- Strategic Alignment
- Whether Samsung Bioepis can effectively leverage ATLATL’s ecosystem to identify and support promising technologies.
- Market Impact
- The pace at which this partnership will accelerate the translation of early-stage science into meaningful medicines for patients.
Related topics